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Calculation Skills: Seasonal Influenza 
Influenza is defined by NICE (2015) as ‘an acute respiratory illness caused by RNA viruses of the 
orthomyxoviridae family’ and there are three types: Influenza A; Influenza B and Influenza C. 
Influenza is identified by the World Health Organisation (WHO) (2012) as having an annual infection 
rate of between 5% and 10% in adults and between 20% and 30% in children. In the UK, it usually 
occurs between October and May and patients who become infected will generally present with 
symptoms which include fatigue; dry cough; headache; sore throat and aching muscles, within 2-3 
days after being exposed to the virus (NICE, 2015). For some, infection with influenza can lead to 
complications which include pneumonia; otitis media; acute bronchitis and severe fever. The risk 
from these complications is greater in those deemed at most risk and this includes people aged over 
65 years; pregnant women; those with underlying long term conditions and the immunosuppressed 
(NHS Choices, 2015).  
Question 1  
Town A has a population of 73,000, of which 18% are children. Based upon the highest predicted 
WHO (2012) annual infection rates, what would the incidence of influenza infection in: 
(i) adults 
(ii) children 
 
Question 2 
Of the adult population in Town A, 20% are over 65, an additional 5% have an underlying long-term 
condition and 2% are pregnant. How big is the ‘at risk’ population of Town A? 
 
Question 3 
Vaccination is seen as the most effective means of preventing infection with influenza and any 
related complications (WHO, 2016). In 2016, only 10% of the population of Town A were vaccinated 
against seasonal influenza. The aim is to increase uptake by 75%. How many people in Town A will 
be vaccinated if this target is achieved? 
 
Question 4 
One of the surgeries in Town A anticipates that 337 patients will need to receive the influenza 
vaccine this year. If the influenza vaccine costs £41.50 for 10 prefilled syringes, how much will the 
cost be for vaccinating these patients (based on price per single vaccine)? 
 
Question 5 
For some at risk patients who have been exposed to influenza and have not been vaccinated, 
treatment with a prophylactic antiviral may be appropriate, as long as they are able to start 
treatment within 36-48 hours of contact. 
During the current epidemic, Damian is considered to be an ‘at risk’ patient due to his chronic 
respiratory disease and is to be prescribed oral oseltamivir prophylactically. He requires 75mg daily 
for up to 6 weeks. 75mg capsules are available in packs of 10 which cost £15.41. Assuming he 
requires the full 6 weeks treatment, what is the cost difference between this prophylactic treatment 
and the influenza vaccine? Calculate your answer using price per capsule rounded up or down to 
nearest pence. 
Answers 
Question 1  
1% of population = 73,000 ÷ 100 = 730 
Adults (82%) = 82 x 730 = 59,860 
Children (18%) = 18 x 730 = 13,140 
(i) Highest predicted rate for adults is 10% of adult population: 10% of 59,860 = 5,986 
(ii) Highest predicted rate for children is 30% of child population: 30% of 13,140 = 3,942 
 
Question 2 
Adults population = 59,860 
Those at risk = 20 + 5 + 2 = 27%  
27% of 59,860 = 16,162 (rounded down) 
 
Question 3 
Target = no. vaccinated in 2016 + 75% 
Population = 73,000 
No. vaccinated in 2016 = 10% of 73,000 = 7300 
75% of 2016 number = 5,475 
7,300 + 5,475 = 12,775 
 
Question 4 
Single vaccine = 41.50 ÷ 10 = 4.15 
337 x 4.15 = £1,398.55 
 
 
Question 5 
Price of prophylactic treatment with antivirals: 
Price per capsule = £15.41 ÷ 10 = £1.54 (rounded down) 
6 weeks treatment = 42 days 
42 x £1.54 = £64.68 
 
Price of vaccine: £4.15 
 
Difference = 64.68 - £4.15 = £60.53 
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